Edelweiss is bullish on Thyrocare Technologies has recommended buy rating on the stock with a target price of Rs 750 in its research report dated May 03, 2018.
Edelweiss' research report on Thyrocare Technologies
In Q4FY18, Thyrocare posted lowest top-line growth—11%—since IPO. This was due to the first-ever decline in Wellness, led by heightened competition, which we have been highlighting for the past six quarters. Despite Q4 being a seasonally strong quarter, rising share of regional PE-backed players, especially in Delhi, coupled with non-recurrence of promotional activity, led to the deceleration. EBITDA margin also fell to 38% from past three quarters’ run rate of 42%. The blip has prompted the company to undertake following changes in strategy: i) shift focus back to B2B; ii) spend 5% of sales on advertising; and iii) promote franchise model in imaging. Given the current macros, we believe successful implementation of this strategy is key.
Though we believe achieving the 25% FY19 revenue growth guidance will be challenging (our estimate 18%), we will wait and watch if the new strategy is successful on a favourable base. Maintain ‘BUY’ with TP of INR750.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.